# HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer

> **NCT03424694** · NA · COMPLETED · sponsor: **CR-CSSS Champlain-Charles-Le Moyne** · enrollment: 199 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** HDR brachytherapy as monotherapy

## Key facts

- **NCT ID:** NCT03424694
- **Lead sponsor:** CR-CSSS Champlain-Charles-Le Moyne
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-22
- **Primary completion:** 2019-06-22
- **Final completion:** 2022-02-22
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03424694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03424694, "HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03424694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*